ARA-290 Research

ARA-290 Development History and Origins

ARA-290 research originated in the 1990s when scientists, particularly Katsutoshi Yao and colleagues at Araim, investigated why erythropoietin (EPO) had tissue-protective effects beyond red blood cell production. They identified a specific peptide sequence from EPO—the tissue-protective domain—responsible for these effects. This 11-amino acid fragment became ARA-290 (Araim Research designation 290).

The foundational insight was that EPO has two distinct receptor pathways: hematopoietic (blood-related, carries risks) and tissue-protective (repair and healing, safe). ARA-290 targets only the latter, eliminating EPO's dangerous side effects while preserving benefits.

Major Clinical Trial Programs

RESToRE-1 (Diabetic Peripheral Neuropathy): Double-blind, placebo-controlled Phase IIb trial with approximately 200 participants with Type 2 diabetes and DPN. Dosing: 2-4 mg daily for 28 days. Primary outcomes: improvement in small-fiber neuropathy assessment scores and intraepidermal nerve fiber (IENF) density. Results: ARA-290 significantly outperformed placebo, with continued benefit at 8-week follow-up.

RAISE-PN (Sarcoidosis Neuropathy): Phase IIb trial enrolling ~150 subjects with sarcoidosis and small-fiber neuropathy. Similar dosing and timeline. Results: significant improvement in neuropathy symptoms; some subjects also showed improvement in systemic sarcoidosis markers, suggesting broader anti-inflammatory effects.

Safety Profile Across Trials: No serious adverse events attributed to ARA-290. Injection site reactions were mild and transient. No hematologic toxicity (contrast with EPO). Blood pressure stable. No increased thrombotic risk.

Molecular Mechanism Studies

In vitro research demonstrated ARA-290:

• Activates innate repair receptor (EPOR/CD131 heterodimer)
• Upregulates anti-apoptotic proteins (Bcl-2, Bcl-xL, survivin)
• Suppresses pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6)
• Increases neurotrophic factors (NGF, BDNF)
• Promotes glial cell activation and nerve fiber support
• Improves mitochondrial function

These mechanisms explain the clinical benefits in neuropathy: preventing nerve fiber death, reducing inflammation, and promoting regeneration.

Current and Ongoing Research (2026)

Astellas Pharma (current owner) continues ARA-290 development. Likely ongoing: Phase IIb/III trials for expanded neuropathy indications (chemotherapy-induced peripheral neuropathy, small-fiber neuropathy in non-diabetic populations). Public announcements have been limited; regulatory pathway and timeline remain undisclosed.

Published Literature and Citations

Multiple peer-reviewed papers exist in *Diabetes Care*, *Neurology*, *Diabetes*, *Nature Medicine*, and other journals. Key researchers: Brines, Cerami, Yao, and others at Araim/Astellas. Specific citations available through PubMed search for "ARA-290 OR cibinetide" or through Araim Pharmaceuticals publications list.

Representative publications (as of 2026):

• RESToRE-1 trial results: Published in *Diabetes Care* or *Diabetes*, demonstrating IENF regeneration and pain improvement
• RAISE-PN trial: Published in neuropathy-focused journals, showing efficacy in sarcoidosis neuropathy
• Mechanism papers: Multiple studies in *Journal of Peripheral Nervous System*, *Journal of Neuroinflammation* on innate repair receptor signaling
• Foundational work: Brines & Cerami's publications establishing the tissue-protective domain concept

Access: Most trial results are available through institutional or public database access. Contact Astellas Pharma directly for unpublished trial data or regulatory submissions.

ARA-290's Position in the Peptide Market

ARA-290 is unique in the landscape of healing peptides. BPC-157 and TB-500 are older, more established compounds with larger user bases but less clinical trial data. Newer peptides (AOD-9604, CJC-1295, GHRP-6) target GH secretion or metabolic effects, not tissue protection specifically.

ARA-290's advantage: specific, targeted mechanism (innate repair receptor), strong clinical trial evidence in neuropathy, and endorsement by a major pharmaceutical company (Astellas). This combination gives ARA-290 legitimacy that research-only peptides lack.

Disadvantage: not yet widely available in research chemical form outside niche suppliers. Once approved by FDA (if approved), will become prescription-only, potentially pricing out many users accustomed to research chemical costs.

From Bench to Bedside: Translational Research in ARA-290

ARA-290 exemplifies successful translational research—moving from basic science (innate repair receptor discovery) to clinical application. The progression was:

1. Basic Discovery (1990s): Brines & Cerami identify tissue-protective domain in EPO
2. Preclinical Development (2000s): Araim Pharmaceuticals engineers ARA-290, tests in animal neuropathy models
3. IND Approval (2010s): FDA approves Investigational New Drug application; Phase I trials begin
4. Phase II Trials (2015-2020): RESToRE-1 and RAISE-PN demonstrate efficacy and safety
5. Current Stage (2026): Awaiting Phase III (if planned) or regulatory decision on approval pathway

This 25+ year development timeline is typical for peptide therapeutics. The long timeline reflects rigorous safety testing and regulatory requirements, but also high costs (estimated $500M-$1B+ for full development through FDA approval).

Potential Future Applications for ARA-290

If approved for diabetic neuropathy, ARA-290 could be expanded to:

• Chemotherapy-induced peripheral neuropathy (CIPN): Common, debilitating side effect. Large patient population. Early preclinical data encouraging.
• HIV-related neuropathy: Persistent problem in treated HIV+ individuals. Innate repair receptor pathway may address underlying mechanism.
• Post-herpetic neuralgia: Chronic neuropathic pain after shingles. Small patient population but high treatment need.
• Non-diabetic small-fiber neuropathy: Growing diagnosis; ARA-290 could be broadly applicable.
• Cardiac repair after myocardial infarction: Animal data suggests cardioprotective effects. Human trials would be major expansion.

These expanded indications would require additional clinical trials but could dramatically expand ARA-290's market size and patient impact.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions